Clinicmicrobiological spectrum of infective endocarditis: from a tertiary care centre in south India

Kanne Padmaja¹, Sukanya Sudhaharan¹*, Lakshmi Vemu¹, Oruganti Sai Satish², Padmasri Chavali¹, Mamidi Neeraja¹

¹Department of Microbiology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
²Department of Cardiology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India

ABSTRACT

Background and Objectives: Infective endocarditis (IE) is a microbial infection of the endothelial surface of the cardiac valves. Rapid diagnosis, effective treatment and prompt recognition of complications are essential, in order to improve the outcome. We retrospectively reviewed and determined the clinical characteristics, microbiological profile and management strategies of IE cases, changing microbial spectrum of pathogens and outcome in Native Valve Endocarditis (NVE) and Prosthetic Valve Endocarditis (PVE) cases.

Materials and Methods: We retrospectively reviewed the medical records of 191 patients, clinically diagnosed with IE, based on modified Dukes criteria, from January 2011 to December 2016. Blood cultures received from all these patients were processed, using BacT/Alert system (bioMerieux, Marcy l’Etoile, France).

Results: Sixty eight (68/191) cases were positive for bacterial pathogens. Twenty four (24/191) cases had PVE and 167/191 had NVE. Nineteen cases (19/24, 79.1%) were PVE positive and forty nine (49/167, 29.3%) were NVE positive. Culture negative endocarditis cases were 123/191 (64.39%). The most common pathogen isolated from NVE cases, in our study was Streptococcus mitis, followed by methicillin-resistant coagulase negative staphylococcus (MRCONS) in PVE. The NVE were treated intravenously with a combination of a β-lactam or glycopeptide with an aminoglycoside, for prolonged period of 4-6 weeks, with a successful outcome. The PVE cases were treated with the appropriate antibiotics as per the antibiotic susceptibility report.

Conclusion: The high morbidity and mortality rates are associated with IE and hence accurate identification of aetiological agents and appropriate antimicrobial therapy is required.

Keywords: Native valve endocarditis, Prosthetic valve endocarditis, Congestive heart failure

INTRODUCTION

Infective endocarditis (IE) is the infection of lining of the heart or the valves, often affecting the mus-
21-50%, over the past three decades with an operative mortality of 5-30%, despite recent advances in diagnosis, medical and surgical management of patients with IE (4). The epidemiology, clinical and microbiologic spectrum of IE is different in Indian population, compared to the west and usually depends on the type of endocarditis (native valve or prosthetic) (5). In most developed countries, NVE accounts for 84.5% of cases and PVE accounts for 7-25% of cases of IE (5). The changing spectrum of IE was described through several data available from the developed countries (4). Chronic rheumatic heart disease was found to be the leading cause of chronic valvular disease, comprised of 46% of all cases. Common organisms causing IE include streptococci, staphylococci, enterococci and fastidious Gram-negative coccobacilli. Other rare causes are mycobacteria, rickettsia, chlamydia and fungi (1). *Staphylococcus aureus* remained the most common cause of bacterial endocarditis in India (6-8).

Inspite of high incidence of rheumatic heart disease and unrepaired congenital heart defects in India and other developing countries, there are relatively limited data on the profile and outcome of IE (4). We retrospectively reviewed and determined the clinical characteristics, microbiological profile and management strategies of IE cases, and also focussed on the changing microbial spectrum of pathogens in NVE and PVE cases with outcome.

**MATERIALS AND METHODS**

This retrospective study was conducted between Jan 2011 to Dec 2016 (for a period of five years). Data collection was based on the systematic review of all-patient charts from medical records department in order to determine the clinical and microbiological spectrum, 191 patients records, definitely diagnosed with IE, based on modified Dukes criteria were reviewed and included. Demographic details such as age, sex, clinical findings, and antibiotic usage were analysed from these cases. Three sets of blood cultures, BacT/Alert FNaerobic and SN aerobic bottles per set (bioMerieux, Marcy l’Etoile, France), were submitted to the microbiology lab, within 24 hours of admission and immediately loaded into BACT/ALERT 3D system. Gram staining was performed on all the positive flagged bottles and further subcultured on Blood (COS bioMerieux, Marcy l’Etoile, France) and Chrome agar (COS bioMerieux, Marcy l’Etoile, France) plates and incubated at 37°C for 24h. The Vitek 2 (bioMérieux, Marcy l’Etoile, France) GN cards (ID GN panel) were used, for accurate identification of Gram-negative pathogens and Vitek 2 AST Cards (N281 panel), for antimicrobial susceptibility testing.

The Vitek 2 GP cards (ID GP) were used, for accurate identification of Gram-positive pathogens, and Vitek 2 AST cards for antimicrobial susceptibility testing.

**RESULTS**

The age range of the patients were 17-80 years, with a male dominance (male: female=1.2:1). The mean age of the IE cases was 30 years, ranging between 21 and 84 years. Majority were in the age group of 41-50 years (Table 1). Among 191 cases, 24/191 cases had PVE, 167/191 had NVE. Blood cultures were positive in 68 patients, out of which 19/24 (79.1%) are PVE positive and 49/167 (29.3%) are NVE positive. Culture negative endocarditis was observed in 123/191 (64.39%) cases (Table 2).

128/191 of our patients (67%) had Rheumatic heart disease (RHD), as an underlying cardiac condition, followed by congenital heart disease 10/191 (5.2%), ventricular septal defect in 10/191 (5.2%), atrial septal defect 10/191 (5.2%), mitral valve prolapse in 9/121 (4.7%) and prosthetic valve disease in 24/191

| Age (year) | Number of patients |
|-----------|--------------------|
| 0-20      | 2                  |
| 21-30     | 15                 |
| 31-40     | 45                 |
| 41-50     | 90                 |
| 51-60     | 32                 |
| 61-70     | 4                  |
| 71-80     | 3                  |

| Type of Endocarditis | N (%) | Culture positive N (%) | Culture negative N (%) |
|----------------------|-------|------------------------|------------------------|
| NVE                  | 167 (87.43%) | 49 (29.3%) | 118 |
| PVE                  | 24 (12.5%) | 19 (79.16%) | 5 |
patients (12.5%) (Table 3).

49/167 cases were culture positive for NVE. The predominant organism isolated include *Streptococcus mitis* (n=20), followed by *Streptococcus sanguinis* (n=13). The complete distribution of causative microorganisms is shown in (Table 4).

Culture positivity was observed in 19/24 cases of PVE. MRCONS was the predominant organism isolated. The complete distribution of causative microorganisms is shown in Table 4.

Fever was the most common clinical feature, observed in majority of cases (n=54, 28.2%), followed by sudden onset of breathlessness (n=24, 12.5%) (Table 5).

A transthoracic echocardiography (TTE) was performed for all the patients. Vegetations were present in 120/191 (62.8%) patients and the most common site of vegetation was mitral valve, which was detected in 65/120 patients (54.16%). The other findings was shown in (Table 6).

### Table 3. Underlying cardiac conditions among IE patients (n=191)

| Variables                   | Number | Percentage (%) |
|-----------------------------|--------|----------------|
| Rheumatic Heart disease     | 128    | 67.0           |
| Prosthetic valves           | 24     | 12.5           |
| Congenital heart disease    | 10     | 5.2            |
| Ventricular septal defect   | 10     | 5.2            |
| Atrial septal defect        | 10     | 5.2            |

### Table 4. Microbial spectrum of NVE &PVE cases

| Microbial spectrum of NVE cases (n=49) | Number of isolates N (%) | Microbial spectrum of PVE cases | Number of isolates N (%) |
|----------------------------------------|---------------------------|--------------------------------|--------------------------|
| *Streptococcus mitis*                  | 20 (40.8)                 | Methicillin Resistant *Staphylococcus aureus* (MRSA) | 4 (21.05) |
| *Streptococcus sanguinis*              | 13 (26.5)                 | Methicillin susceptible *Staphylococcus aureus* (MSSA) | 2 (10.52) |
| *Streptococcus pyogenes*               | 3 (6.12)                  | Methicillin Resistant Coagulase negative *Staphylococcus* (MRCONS) | 7 (36.84) |
| *Streptococcus pneumoniae*             | 1 (2.04)                  | *Klebsiella pneumoniae* | 3 (15.78) |
| *Granulicatella adiacens*              | 1 (2.04)                  | *Achromobacter denitrificans* | 3 (15.78) |
| *Abiotrophia defectiva*                | 1 (2.04)                  | *Burkholderia cepacia* | 3 (15.78) |
| *Gemella morbillorum*                  | 2 (4.08)                  |                                |                          |
| Methicillin Resistant *Staphylococcus aureus* (MRSA) | 1 (2.04) |                                |                          |
| Methicillin susceptible *Staphylococcus aureus* (MSSA) | 2 (4.08) |                                |                          |
| *Brucella melitensis*                 | 2 (4.08)                  |                                |                          |
| *Brevundimonas diminuta*               | 1 (2.04)                  |                                |                          |
| *Stenotrophomonas maltophilia*         | 1 (2.04)                  |                                |                          |
| *Corynebacterium diphtheriae*          | 1 (2.04)                  |                                |                          |
**DISCUSSION**

IE is the infection of the endothelial surface of the heart (2). Despite advances in medical, surgical and critical care interventions, the incidence of IE has not been changed over the past two decades (2, 9). Active IE is lethal, if not aggressively treated with antibiotics, combined or not associated with surgery (1).

In developed countries, most of the studies on IE, had been seen in elderly and have demonstrated a gradual increase in the mean age of IE patients (1). But majority of our patients were younger and our data are consistent with previously published studies from developing countries (2), which may be due to the higher rate of chronic rheumatic heart disease (CRHD). In the European heart survey, it was observed that bacterial endocarditis accounted for 26% and most of the affected patients were elderly group with an age of more than 70 years but in the Indian populations, it is still common in younger age group, as similar to our study (10).

In our study, CRHD was the most common predisposing factor similar to other studies (9, 11, 12). In a recent study from Turkey, CRHD was found to be the leading cause of chronic valvular disease, which comprised of 46% of all cases (13).

Our study, also confirmed many clinical features of endocarditis, occurring in other parts of the world. Fever was the most common clinical feature (28.2 %), observed among our patients with similar percentage reported by other study (14). The lack of fever should not exclude the diagnosis of IE, in a patient with suggestive clinical features.

Diagnosis of IE by TTE/TEE (Trans oesophageal echocardiography) is a non-invasive and available method of choice, in order to evaluate the presence of vegetations (14). Thus, TEE is highly sensitive for detecting IE. In our study, vegetations were detected in 62.8% of patients by TTE only. Mitral valve was the most common valve affected in our study (54.16%), similar to other studies (4, 15).

We have observed in our study, that NVE is common (87.4%), which is in close agreement with previous studies (9, 16), where as Senthil et al. (4) have observed, in 95.7% cases.

PVE accounted for 7-25% of cases of IE, in most developed countries (9). In developing countries like India, Senthil et al. (4) observed PVE in 4.3% of cases and Mario et al. (9) in 30% of cases. PVE depends on the time of onset of endocarditis, following the valve replacement. Approximately 40-60% of early onset PVE is caused by both Gram- positive cocci and Gram- negative bacteria. In our study the frequency of IE involving prosthetic valves was around 12.5% and mostly caused by Gram-positive cocci (9).

IE is caused by a wide variety of pathogens. Most commonly staphylococcus spp. and streptococcus spp. are identified, but new species are constantly being discovered (2). Common species causing IE include streptococci, staphylococci, enterococci and fastidious Gram-negative coccobacilli. Other rare causes are mycobacteria, rickettsia, chlamydia and fungi (2).

*S. aureus* is responsible for 30 to 65% of NVE in India, thus Staphylococcus incidence is on the rise. Our study also showed that *S. viridans* has overcome *S. aureus*, as the most common cause of IE particularly in NVE. The previous Indian study by Garg et al. has shown that streptococci are the most common isolate (17), which was consistent with our observation.

Murdoch et al. (15) observed that *S. aureus* is the most common cause of IE worldwide, due to the presence of risk factors such as intravenous drug use and invasive devices. The increasing emergence of *Staphylococcus* in west, is accounted by an increasing geriatric population, rising drug abuse, increasing nosocomial infections and use of prosthetic devices. *S. aureus* was the most common causative agent identified in North America, Turkey and Saudi Arabia (10), but in our study we isolated 6.1% of *S. aureus* isolates.

Coagulase-negative staphylococci (CONS) cause about 6% of NVE, but rarely acute IE. In our study, we observed that CONS was isolated in most cases of PVE (36.8%).

The high yield of CONS is usually surprising, because isolation of these organisms suggest the skin contamination. But in the presence of prosthetic valve, isolation of this pathogen should be considered significant.

Thus, the incidence of pneumococcal endocarditis is not exactly known, but few clinical studies have estimated the prevalence to be less than 3%. Usually *Streptococcus pneumoniae* is known to cause respiratory tract infections but many recent studies have greatly emphasized on their role, in causing bacterial endocarditis as similar to our study. Because as such pneumococcal bacteremia is usually the consequence of lung infection.

A case of PVE caused by *Achromobacter denitrifi- cans* in a 17 years old patient, with known congenital
heart disease and aortic stenosis who had undergone surgical replacement of mitral valve has been examined in our study. The most common manifestation of infection documented with this organism is bacteremia, with a mortality rate of more than 50%. PVE, usually develops between 4-6 months of valve replacement due to *Achromobacter xylosoxidans* subsp. denitrificans (18), as also seen in our case (19). It is probable that our patient acquired the valve infection, either intra-operatively or postoperatively.

Thus some unusual IE pathogens such as NVS, *Gemella morbillorum* and *Brucella melitensis* that are slow growing and difficult to be isolated from blood cultures, were isolated from our cases because of availability of commercial liquid media that supports the growth of the pathogens and advanced automated systems.

NVS are the etiological agents of IE in 5%-6% of cases (20). We isolated *G. adiacens* from a NVE patient. Giuliano et al. (21) also reported NVS in a patient with IE caused by *G. adiacens*, similar to our case (22). In our case, the route of entry of NVS into the bloodstream was not known and these organisms are assumed to have originated from the oral cavity, as the patient had bad oral hygiene, for which she had undergone dental manipulations several times, before the episode of IE.

*Gemella* species are small Gram-positive cocci, a rare cause of endocarditis that have been increasing-ly reported since 1982. Taimur et al. reported twenty-four cases of *Gemella* endocarditis in the literature, up to 2010 (23). We reported only 2 cases of NVE caused by *G. morbillorum* in our study.

*Brucella* IE is an uncommon, but life threatening complication of brucellosis, it is observed in less than 2% of the brucellosis cases. The aortic valve is the most commonly affected cardiac valve (24). We also had a similar case of *Brucella* endocarditis (BE), where aortic valve was affected and *B. melitensis*, isolated from aortic valve tissue and also blood cultures. Mustafa et al. reported 31 cases of native BE (25).

Thus, bacterial isolation from valvular tissue is not always possible; healed endocarditis, broad spectrum perioperative antibiotic therapy, systemic hypothermia, haemodilution and cold cardioplegia reduce the possibility of pathogen isolation from the infected tissue (1). In our study, *Brucella* was isolated from aortic valve tissue from a case of BE.

Corynebacteria have been shown to be responsible for 0.2 to 0.4% of IE cases, in native valve (26). In our study we reported a case of NVE in a 9 years old child with Tetrology of Fallot (TOF) with sub-aortic ventricular septal defect (VSD) caused by non-toxigenic (NT) *C. diphtheriae* biotype mitis. But due to cardiac arrest patient was succumbed to death, though aortic valve replacement was planned (27). The NT *C. diphtheria* probably entered the body, either subsequent to skin and/or throat colonization or a percutaneous trauma.

*Stenotrophomonas maltophilia* is a nosocomial pathogen resistant to multiple antibiotics and is a rare cause of endocarditis and carries high mortality and morbidity (28). In our study, *S. maltophilia* was identified as a cause of active IE from a native aortic valve of patient.

Positive blood culture is a major diagnostic criterion for IE. Blood culture is often negative in Indian population, compared to western due to prior antimicrobial therapy. Failure to culture the organism may result from inadequate antimicrobial technique, infection with highly fastidious pathogen or most importantly, because of the administration of antimicrobial agent before blood cultures are performed (2).

Most of our patients had previous use of antibiotics prior to hospital admission, which was the main reason for high number of culture negative cases. This is consistent with previous reports (17), in which the number of patients with culture negative endocarditis, received antibiotics in the 2 weeks prior to diagnosis, was found to be as high as 64.3% in our cases. Senthil et al. (4) reported 76.7% of CNE, which was still more higher, compared to our study. In Syed Mohammed study, 46.7% of patients were found to be culture negative (14).

The total surgeries done for IE in our study was 32 (35.16%), the most common was mitral valve replacement 22 (11.5%), followed by aortic valve replacement 8 (4.18%) and VSD closure in 2 (1.04%) patients. All patients with streptococcal IE, should be treated for at least 2 weeks in hospital and observed for cardiac and non-cardiac complications.

IE caused by methicillin-resistant *S. aureus* (MRSA), is a therapeutic challenge as most strains are also resistant to most aminoglycosides. If the clinical course is complicated, treatment should be as for PVE.

Coagulase-negative species (CONS), causing PVE within the first year after valve replacement are usually methicillin-resistant. Therapy of choice is a combination of vancomycin and rifampicin for at least 6 weeks with the addition of gentamicin for the initial
two weeks (28).

Enterococci are generally resistant to a wide range of antimicrobial agents including aminoglycosides (MIC for gentamicin 4-64 mg/l). Duration of treatment should be at least 4 weeks for the combination and at least 6 weeks in complicated cases, for patients having symptoms for more than 3 months, and for patients with PVE (28).

Aminoglycosides are often used in combination with a cell wall-active agent (β-lactam or vancomycin), for synergy in the treatment of IE caused by staphylococci, streptococci and enterococci. Cell wall-active agents increase aminoglycoside entry into bacteria, and therefore synergy requires dosing in close temporal proximity to one another (29).

All the NVE cases, in our study were treated with a combination of a β-lactam or glycopeptide with an aminoglycoside mostly ceftriaxone and gentamicin, intravenously for prolonged period of 4-6 weeks, with a successful outcome.

All the PVE cases, in our study were treated with vancomycin, in case of Gram-positive pathogens and meropenem was used against Gram- negative pathogens.

Jain et al. (12) reported the mortality rate in patients who underwent surgery was 6 (8.3%) and Fahriye et al. (10) showed mortality of 30% and both studies observed that CHF was the most common complication leading to death. Loupa et al. reported an overall mortality rate of 16% (12). Whereas, mortality rate among our patients with IE was 13 (40.6%), which was comparatively high, compared with other study. Main causes of death in our study were sepsis in 10 (31.25%), cerebral embolism in 2 (6.25%) and cardiac arrest in 1 patient (3.12%).

CONCLUSION

Despite recent advances, the management of IE remains a serious and challenging problem. Patients with endocarditis need more accurate clinical evaluation, high index of clinical suspicion, early diagnosis for at risk populations, which can prevent disease progression.

The accurate identification of aetiological agents and appropriate antimicrobial therapy are associated with IE. We observed that Streptococcus mitis was the most predominant pathogen that led to bacterial endocarditis in our cases. All our cases were promptly treated with conservative management. And the cases which did not respond were posted for surgery with good clinical outcome. Congestive heart failure was the most frequent infective endocarditis complication as well as indication for surgery. In-hospital mortality rate of patients was unexpectedly low.

Results obtained in our study emphasizes that there is an urgent need for implementation of strict infection control measures and practices to reduce the incidence of IE which is most often due to hospital acquired pathogens. Henceforth surveillance studies, should be initiated with the existing global scenario in prevention, diagnosis and management of IE cases.

REFERENCES

1. Kucukates E, Gultekin N, Bagdatli Y. Cases of active infective endocarditis in a university hospital during a 10-year period. J Pak Med Assoc 2013;63:1163-1167.
2. Khan NU, Farman MT, Sial JA, Achakzai AS, Saghir T, Ishaq M. Changing trends of infective endocarditis. J Pak Med Assoc 2010;60:24-27.
3. Beynon RP, Bahl VK, Prendergast BD. Infective endocarditis. BMJ 2006; 333:334-339.
4. Senthilkumar S, Menon T, Subramanian G. Epidemiology of infective endocarditis in Chennai, South India. Indian J Med Sci 2010;64:187-191.
5. Nunes MC, Gelape CL, Ferrari TC. Profile of infective endocarditis at a tertiary care center in Brazil during a seven-year period: prognostic factors and in-hospital outcome. Int J Infect Dis 2010;14:e394-398.
6. Wallace SM, Walton BI, Kharbanda RK, Hardy R, Wilson AP, Swanton RH. Mortality from infective endocarditis: clinical predictors of outcome. Heart 2002;88:53-60.
7. Ghosh S, Sahoo R, Nath RK, Duggal N, Gadpayle AK. A study of clinical, microbiological, and Echocardiographic profile of patients of infective endocarditis. Int Sch Res Notices 2014;2014:340601.
8. Gupta A, Gupta A, Kaul U, Varma A. Infective endocarditis in an Indian setup: Are we entering the ‘modern’ era? Indian J Crit Care Med 2013;17:140-147.
9. Nunes MC, Gelape CL, Ferrari TC. Profile of infective endocarditis at a tertiary care center in Brazil during a seven-year period: prognostic factors and in-hospital outcome. Int J Infect Dis 2010;14:e394-398.
10. Agca FV, Demircan N, Peker T, Ari H, Karaagac K, Ozluk OA, et al. Infective endocarditis: a tertiary referral centre experience from Turkey. Int J Clin Exp Med 2015;8:13962-13968.
11. Kothari SS, Ramakrishnan S, Bahl VK. Infective en-
12. Jain SR, Prajapati JS, Phasalkar MA, Roy BH, Jayram AA, Shah SR, Singh T, et al. Clinical spectrum of infective endocarditis in a tertiary care centre in western India: A prospective study. *IJCM* 2014;5:177-187.

13. Tuğcu A, Yıldırımtürk O, Baytaroğlu C, Kurtoğlu H, Köse O, Sener M, et al. Clinical spectrum, presentation, and risk factors for mortality in infective endocarditis: a review of 68 cases at a tertiary care center in Turkey. *Turk Kardiyol Dern Arş* 2009;37:9-18.

14. Hosseini SM, Bakhshian R, Moshkani Farahani M, Abdar Esfahani M, Bahrami A, Sate A. An observational study on infective endocarditis: A single center experience. *Res Cardiovasc Med* 2014;3(4):e18423.

15. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century. *Arch Intern Med* 2009;169:463-473.

16. Loupa C, Mavroidi N, Boutsikakis I, Paniara O, Deligarou O, Manoli H, et al. Infective endocarditis in Greece: a changing profile. Epidemiological, microbiological and therapeutic data. *Clin Microbiol Infect* 2004;10:556-561.

17. Siddiqui BK, Tariq M, Jadoon A, Alam M, Murtaza G, Abid B, et al. Impact of prior antibiotic use in culture-negative endocarditis: review of 86 cases from southern Pakistan. *Int J Infect Dis* 2009;13:606-612.

18. Derber C, Elam K, Forbes BA, Bearman G. *Achromobacter* species endocarditis: A case report and literature review. *Can J Infect Dis Med Microbiol* 2011;22(3):e17-e20.

19. Padmaja K, Lakshmi V, Amrash MR, Mishra RC, Chikkala R. Prosthetic valve endocarditis with aortic root abscess due to *Achromobacter denitrificans* a case report. *Int J Infect Control* 2013;9(1):1-5.

20. Lin CH, Hsu RB. Infective endocarditis caused by nutritionally variant streptococci. *Am J Med Sci* 2007;334:235-239.

21. Giuliano S, Caccese R, Carfagna P, Vena A, Falcone M, Venditti M. Endocarditis caused by nutritionally variant streptococci: a case report and literature review. *Infez Med* 2012;20:67-74.

22. Padmaja K, Lakshmi V, Subramanian S, Neeraja M, Krishna SR, Satish OS. Infective endocarditis due to *Granulicatella adiacens*: a case report and review. *J Infect Dev Ctries* 2014;8:548-550.

23. Taimur S, Madiha R, Samar F, Bushra J. *Gemella morbillorum* endocarditis in a patient with a bicuspid aortic valve. *Hellenic J Cardiol* 2010; 51:183-186.

24. Keles C, Bozbuga N, Sismanoglu M, Guler M, Erdogan HB, Akinci E, et al. Surgical treatment of *Brucella* endocarditis. *Ann Thorac Surg* 2001;71:1160-1163.

25. Inan MB, Eyleten ZB, Ozcinar E, Yazicioglu L, Sirak M, Eryilmaz S, et al. Native valve *Brucella* endocarditis. *Clin Cardiol* 2010;33(2):E20-E26.

26. Wilson AP. The return of *Corynebacterium diphtheriae*: the rise of non-toxicogenic strains. *J Hosp Infect* 1995; 30:306-312.

27. Padmaja K, Lakshmi V, Sandhya K, Satish OS, Kumar KLN, Amrash MR, et al. Native valve endocarditis due to non toxigenic strain of *Corynebacterium diphtheriae* in a child: case report & review of litterature. *J Immunol Tech Infect Dis* 2016; 5:3.

28. Lakshmi S, Rai MP, Castro JG. *Stenotrophomonas maltophilia* endocarditis of the native aortic valve: case report and review of literature. *Infect Dis Clin Pract* 2015;23(5):231-234.

29. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American heart association: a guideline from the American heart association rheumatic fever, endocarditis, and kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. *Circulation* 2007;116:1736-1754.